| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 389.9 | 384.0 |
| Gross profit | 243.4 | 222.4 |
| Profit before tax | 21.8 | 42.4 |
| Net income | 22.4 | 27.8 |
| EPS (diluted, $ a share) | $0.33 | $0.41 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -19.4% |
|---|---|
| Revenue, year on year | +1.5% |
| Gross margin | 62.4% |
| Operating margin | 8.3% |
10-Q filed with the SEC, NASDAQ: LNTH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Lantheus Holdings, Inc.: key numbers
- Share price
- $101.72Close, Nov 16
- Market cap
- $6.65B
- Shares outstanding
- 65.4MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- In Vitro & In Vivo Diagnostic SubstancesSIC 2835
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Lantheus Holdings, Inc.
All →Lantheus Holdings Divestiture to PharmaLogic Holdings Corp.
Lantheus Holdings has entered into a definitive agreement to sell its contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey manufacturing facility to PharmaLogic. As part of the transaction, the parties will enter into a long-term supply agreement where PharmaLogic's Agilera franchise will manufacture lutetium Lu 177 dotatate for Lantheus.
- Counterparty
- PharmaLogic Holdings Corp.
Lantheus Holdings Financial Results
Lantheus Holdings reported Q3 2026 financial results with worldwide revenue of $389.9 million and adjusted EPS of $1.68. The company also highlighted the pending $8.0 billion acquisition by Curium and the recent FDA approvals of TAUKLARIFY and BRAVNETSA. Due to the pending merger, the company has suspended its full-year 2026 financial guidance.
Lantheus Holdings M&A Deal with Curium US Holdings LLC
Lantheus Holdings and Curium US Holdings received a 'Second Request' for information from the FTC regarding their pending merger agreement. This request extends the HSR Act waiting period, though both parties still expect the transaction to close in the first half of 2027.
- Counterparty
- Curium US Holdings LLC
Lantheus Holdings M&A Deal with Curium US Holdings LLC
Lantheus Holdings stockholders approved the adoption of the merger agreement with Curium US Holdings LLC, whereby Lantheus will be acquired and become a wholly owned subsidiary of Curium. The approval was obtained at a special meeting held on October 14, 2026, with over 55 million shares voting in favor of the transaction. Stockholders also approved the advisory compensation proposal related to the merger.
- Counterparty
- Curium US Holdings LLC
Lantheus Holdings M&A Deal with Curium US Holdings LLC
Lantheus Holdings provided a status update on its pending merger with Curium US Holdings, disclosing supplemental proxy information to resolve several stockholder lawsuits and demand letters. The litigation alleged that the original proxy statement omitted material information regarding financial projections and potential conflicts of interest; the company denied all allegations but provided the disclosures to avoid the costs of litigation ahead of the October 14, 2026, stockholder vote.
- Counterparty
- Curium US Holdings LLC
Lantheus Holdings M&A Deal with Curium US Holdings LLC
Lantheus Holdings provided a regulatory update on its pending merger with Curium US Holdings LLC, noting that Curium voluntarily withdrew and refiled its HSR Act pre-merger notification to provide the FTC with additional time for review. The new 30-day waiting period is set to expire on October 21, 2026, and the parties still expect to close the transaction in the first half of 2027.
- Counterparty
- Curium US Holdings LLC